World Journal of Vaccines

Volume 3, Issue 1 (February 2013)

ISSN Print: 2160-5815   ISSN Online: 2160-5823

Google-based Impact Factor: 0.67  Citations  

Vaccines in Non-Small Cell Lung Cancer

HTML  XML Download Download as PDF (Size: 120KB)  PP. 19-24  
DOI: 10.4236/wjv.2013.31004    4,109 Downloads   7,025 Views  Citations


Immunotherapy as an option of treatment in cancer has experienced an important development with the inclusion of vaccines. In lung cancer this type of treatment has emerged and vaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines, and dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the vaccines most widely studied. Their promising results with benefit in survival and limited toxicity in preclinical and clinical trials have led to phase III trials with results eagerly awaited. Other vaccines have been investigated, but results were not favorable or are still pending. Hopefully, vaccines could be an additional instrument for the treatment of lung cancer in the adjuvant or metastatic setting as time will unveil the results of current and future trials.

Share and Cite:

L. Corrales-Rodriguez, N. Blais and D. Soulières, "Vaccines in Non-Small Cell Lung Cancer," World Journal of Vaccines, Vol. 3 No. 1, 2013, pp. 19-24. doi: 10.4236/wjv.2013.31004.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.